Grifols SA

ES

GRLS

Health Care

6.3 ₽

Current price

Hold
6.3 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    430 / 1361

  • Position in country

    208 / 287

  • Return on Assets, %

    0.8

    -40.3

  • Net income margin, %

    4.3

    -180

  • EBITDA margin, %

    18.9

    -168.2

  • Debt to Equity, %

    173.6

    3.2

  • Intangible assets and goodwill, %

    44.9

    0.2

  • Revenue CAGR 3Y, %

    7.2

    12.5

  • Total Equity change 1Y, %

    -2

    -9

  • Revenue Y, % chg

    12.3

    0

  • P/E

    68.3

    31

  • P/BV

    0.7

    1.8

  • P/S

    0.6

    10.3

  • EV/S

    2.6

    7.5

  • EV/EBITDA

    15

    -1.6

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    141.3

    131.1

  • Forward P/E

    6.9

    21.4

  • Dividend Yield, %

    9.8

    1.1

  • Forward Dividend Yield, %

    2.6

    0.1

  • Expected dividend per share

    0.1

    0

  • Payout Ratio, %

    0

    0

  • Dividend Ex Date

    2021-06-03

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • CSL Ltd

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Celltrion Inc

    00%

  • Grifols SA

    00%

  • Moderna Inc

    00%

  • AbbVie Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Spain

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    5602.5

  • Ticker

    GRFS.OQ

  • ISIN

    US3984384087

  • IPO date

    2006-05-17

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-03-08

  • Date fact. publication of reports

    2023-12-31

Company Description

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.